Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a <i>CKJ</i> controversy-Reference-Cited by-同舟云学术

Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a CKJ controversy

Published:2024-08-12 Issue:9 Volume:17 Page:
ISSN:2048-8505
Container-title:Clinical Kidney Journal
language:en
Short-container-title:

Author:

Caravaca-Fontán Fernando¹,del Vecchio Lucia²,Praga Manuel³,Floege Jürgen⁴,Zoccali Carmine⁵⁶⁷

Affiliation:

1. Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12) , Madrid , Spain

2. Department of Nephrology and Dialysis, ASST Lariana , Como , Italy

3. Department of Medicine, Complutense University , Madrid , Spain

4. Department of Nephrology and Rheumatology and Department of Cardiology, RWTH University Hospital Aachen , Aachen , Germany

5. Renal Research Institute , NY , USA

6. Institute of Molecular Biology and Genetics, (Biogem), Ariano Irpino , Italy

7. Associazione Ipertensione Nefrologia Trapianto Renale (IPNET), c/o Nefrologia, Grande Ospedale Metropolitano , Reggio Calabria, Italy

Abstract

ABSTRACT Integrating sodium-glucose co-transporter 2 inhibitors (SGLT2i) into the treatment for chronic kidney disease (CKD) has marked a significant therapeutic advance in nephrology. Clinical trials such as DAPA-CKD and EMPA-KIDNEY have demonstrated the beneficial effects of SGLT2i in slowing CKD progression and reducing proteinuria. However, the applicability of these results to patients with glomerulonephritis is still unresolved due to various limitations. This manuscript combines the evidence supporting the use of SGLT2i in glomerular diseases, highlights the limitations and strikes a conclusive balance on their role in clinical practice.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ckj/advance-article-pdf/doi/10.1093/ckj/sfae237/58802381/sfae237.pdf

Reference14 articles.

1. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy;Wheeler;Kidney Int,2021

2. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial;Wheeler;Nephrol Dial Transplant,2022

3. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial;Judge;Lancet Diabetes Endocrinol,2024

4. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis;Caravaca-Fontán;Nephrol Dial Transplant,2024

5. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials;Neuen;Circulation,2022